Similar Articles |
|
The Motley Fool April 19, 2011 Bryan White |
Rising Star Buy: Medco Health Medco has a much brighter future than its current stock price implies. |
The Motley Fool November 4, 2009 Brian Orelli |
This One Is Thriving in a Recession Saving customers money makes it easy for Medco. |
The Motley Fool February 16, 2005 Brian Gorman |
Medco's Double-Edged Sword The pharmacy benefit manager's latest financial report indicates that its business remains robust. But is it at the expense of retail pharmacies? |
The Motley Fool November 3, 2010 Brian Orelli |
A Generic Prescription for Double-Digit Growth MedcoHealth Solutions has it. |
The Motley Fool December 6, 2007 Selena Maranjian |
Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall. |
The Motley Fool February 25, 2009 Brian Orelli |
The Best Kind of Generic Growth Pharmacy benefit managers profit from penny-pinchers. |
The Motley Fool April 29, 2010 Brian Orelli |
A Prescription to Investigate Further Let's not worry just yet about Medco's margins. |
The Motley Fool July 30, 2009 Brian Orelli |
A Good Business Model for Bad Times Some businesses benefit when people are hurting. It's a beautiful time to be a pharmacy benefit manager, since that business model essentially results in them making more money when their customers save money. |
The Motley Fool August 1, 2008 Brian Orelli |
Express Scripts Gets More Generic Pharmacy benefits manager Express Scripts may not have grown the top line by much in the second quarter, but using more generic drugs had a positive effect on the bottom line. |
The Motley Fool October 24, 2006 Brian Gorman |
Medco's Fringe Benefits Recent developments will present some challenges, but Medco remains a solid long-term investment. |
The Motley Fool May 4, 2011 Jason Knapp |
Generic Drugs and Old People Could Make You Rich CVS hasn't generated market-beating returns yet -- but it will. |
The Motley Fool July 29, 2004 Brian Gorman |
Express Scripts' Bad Day Express Scripts joins other pharmacy benefit managers (PBM) embroiled in legal controversy. But the company, and its competitors, will eventually emerge from the fray and their stocks may then be worth another look. |
The Motley Fool April 27, 2005 Brian Gorman |
Cautious on Medco Medco's earnings were respectable, but for now investors may want to step back. |
The Motley Fool June 30, 2011 David Williamson |
Pharmacy Benefits Delivering Drama CVS claims another Medco client and one messy split. |
The Motley Fool October 29, 2009 Brian Orelli |
Expressing Itself Nicely A nice quarter for Express Scripts. |
The Motley Fool February 14, 2005 Brian Gorman |
GM Pulls Out of Walgreen The pharmacy's mail-order policy spurs the automaker's cost-containment decision. |
The Motley Fool June 30, 2005 Brian Gorman |
The Co-Pay Effect Higher co-payments look like the wave of the future, and investors should expect the trend to boost major generic players like Teva Pharmaceutical, Mylan Laboratories, and Novartis. |
BusinessWeek March 7, 2005 Amy Barrett |
A Drug Company On Growth Hormones By adding Accredo to its portfolio, Medco gains a strong presence in the area of specialty drugs. Investors sent Medco's stock down slightly on news of the deal. But they give company chief David B. Snow Jr. credit for putting Medco in a position to capitalize on new opportunities. |
CFO June 1, 2010 Alix Stuart |
"This Is the Era of Smarter Medicine." A prescription-drug provider says it can thrive even as it helps drive down health-care costs. An interview with Richard Rubino, CFO, Medco Health Solutions Inc. |
Managed Care September 2007 |
Income Said To Influence Use of Generics An observational analysis of pharmacy claims collected from 2001 to 2003 finds that where a person lives and the socioeconomic implications of that location have a lot do with his use of generic drugs. |
The Motley Fool February 22, 2005 Brian Gorman |
Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look. |
The Motley Fool March 22, 2010 Brian Orelli |
Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio. |
Managed Care November 2005 |
Recently Introduced Generics Helped Pbm Control Its Costs The top five generic drugs released over the past three years reduced pharmacy spending by 4.8 percent largely due to the timing of the release of generic products to the market. |
The Motley Fool November 2, 2005 Brian Gorman |
Medco's Bitter Pill The pharma benefits manager has hit a speed bump but looks well-positioned for the long haul. Investors, take note. |
The Motley Fool April 7, 2011 Brandon Glenn |
"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors. |
The Motley Fool August 31, 2011 Shubh Datta |
CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue. |
The Motley Fool April 30, 2008 Brian Orelli |
Medco's Far-From-Generic Quarter Pharmacy benefit manager Medco Health Solutions benefits from new generic drugs. |
Managed Care September 2006 |
Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association. |
The Motley Fool July 25, 2011 Brian Orelli |
Express-Medco: Just What the Doctor Prescribed In perhaps the most obviously beneficial merger ever, Express Scripts announced its plan to buy Medco Health Solutions for $29.1 billion. |
The Motley Fool November 9, 2005 Brian Gorman |
Caremark's Room to Grow Fickle investors may fret about near-term growth, but the pharmacy benefit manager is prepared for the long haul. Investors looking for a long-term holding may want to mark a place in their portfolio for this company. |
The Motley Fool October 22, 2010 Roger Friedman |
3 Health-Care Stocks for Your Watchlist There's money to be made in health care. But finding the right plays, especially among health care providers, can prove confounding. |
The Motley Fool August 16, 2010 Brian Orelli |
The Fine Line Between Saving Money and Making It Medco's trying to walk it. |
The Motley Fool October 28, 2010 |
Our Top Stock Idea Our investing community's latest prime pick -- Medco Health Solutions. |
The Motley Fool August 3, 2004 Jeff Hwang |
Generics Pump Watson The firm's strong growth in generic drug sales eases its branded product pains. The stock is up more than 10%. |
The Motley Fool February 28, 2005 Brian Gorman |
Medco Covers Its Bases Medco's purchase of Accredo is a nod to future growth in biotech drug spending. |
The Motley Fool August 15, 2007 Mary Dalrymple |
Drug Costs Giving You a Headache? If you want to cut your prescription drug costs, you can do more than just switch to generic brands. Shop around and ask questions. It's your health, and it's your money. |
The Motley Fool June 13, 2005 Brian Gorman |
Walgreen Strikes Back The traditional drugstore operator is expanding its mail-order business. This should be a welcome sign to investors. |
The Motley Fool October 27, 2005 Stephen D. Simpson |
Can ESRX Spell P-r-o-f-i-t-s? A company focused on lowering medical costs sounds like a good idea, but investors should dig deeper. While pharmaceutical benefits manager Express Scripts offers high growth and high valuation, it may also offer higher-than-average risk. |
The Motley Fool September 27, 2006 Michael P. Cecil |
A Drug-Price Avalanche? Wal-Mart shapes the way America buys many products, and its recently announced $4 program for generic prescription drugs may be the harbinger of a major change in prescription-drug sales. |
The Motley Fool February 28, 2008 Brian Lawler |
Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year. |
The Motley Fool October 16, 2006 Brian Lawler |
The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note. |
The Motley Fool June 12, 2006 Brian Gorman |
Biogeneric Payoff? A new report indicates that spending on specialty drugs increased 17.5% in 2005. This growth bodes well for makers of biotech drugs, which make up a large portion of the specialty drug category. Investors, take note. |
The Motley Fool November 8, 2006 Michael P. Cecil |
CVS/Caremark: A Brobdingnagian Drug Seller The merger of CVS and Caremark says a lot about pharmaceutical retailers and pharmacy benefit mangers trying to deal with a rapidly changing paradigm. |
CFO March 1, 2012 David McCann |
Companies May Win This Drug War The conflict between Express Scripts and Walgreen just might lead to lower drug-benefit costs for companies. |
The Motley Fool January 13, 2009 Dayana Yochim |
Fiscal Fitness '09: 6 Ways to Score Cheap(er) Drugs Save more than $200 on prescriptions. |
Managed Care May 2006 John Carroll |
Effective Ways To Increase Usage of Generics Generics is one of the few areas where insurance plans can economize effectively. BlueCross & BlueShield of North Carolina is one of many insurers that are changing members' and prescribers' behavior. |
Managed Care October 2005 |
Health Plans Pay Less When PBM Owns Mail-Order Pharmacy The ongoing debate on whether health plans pay more for drugs when using a mail-order pharmacy owned by a pharmacy benefits manager (PBM) or when the mail-order pharmacy is not owned by a PBM may be closer to resolution. |
Managed Care November 2005 John Carroll |
FTC Report Arms PBMs In Battle With Drugstores Congress passed the Medicare Modernization Act allowing pharmacy benefits managers to participate in Medicare Part D. |
Managed Care April 2006 Martin Sipkoff |
Blues Plan's Bold Move Brings Generics Savings Blue Cross & Blue Shield of North Carolina is waiving its copayments for generic drugs in a unique six-month pilot program. |
Managed Care January 2007 Martin Sipkoff |
Employers Want Plans & PBMs To Push Hard for Generics Health insurers' aggressive stand on members' use of generic drugs can attract new clients, but does it interfere with the physician-patient relationship? |